Cagri + Semaglutide (1 Box) - 99% Purity Research Peptide

✅ Sold as 1 Full Box (10 Vials) Each vial = 5/10mg | Research Use Only
(18)
170.10

Cagri + Semaglutide - Dual-pathway research combination targeting amylin and GLP-1 receptors. Studied in appetite regulation, metabolic function, glucose metabolism, and body-weight research. Combines two complementary mechanisms in one research formulation.

Dual-pathway combination (Cagrilintide + Semaglutide)

Targets amylin and GLP-1 receptor pathways for metabolic and appetite-regulation research

Research-grade combination

        SPECIAL OFFER

          Please select all product options

          Product was out of stock

          share

          ✅ HPLC Purity Analysis
          Confirms the peptide is ≥99% pure

          ✅ Mass Spectrometry
          Verifies the exact molecular identity

          ✅ Heavy Metals Screening
          Lead, arsenic, cadmium & mercury - Pass

          ✅ Endotoxins (LPS)
          Bacterial endotoxin levels - Pass

          ✅ Sterility Testing
          No microbial contamination - Pass

          ✅ TFA Content
          Residual trifluoroacetic acid - Not Detected

          ✅ Net Peptide Content
          Actual peptide mass per vial verified

          ✅ HPLC Purity Analysis
          Confirms the peptide is ≥99% pure

          ✅ Mass Spectrometry
          Verifies the exact molecular identity

          ✅ Heavy Metals Screening
          Lead, arsenic, cadmium & mercury - Pass

          ✅ Endotoxins (LPS)
          Bacterial endotoxin levels - Pass

          ✅ Sterility Testing
          No microbial contamination - Pass

          ✅ TFA Content
          Residual trifluoroacetic acid - Not Detected

          ✅ Net Peptide Content
          Actual peptide mass per vial verified

          Description Customers Reviews

          Description

           

          Cagri + Semaglutide is a combination research compound featuring cagrilintide and semaglutide. Cagrilintide is an amylin analogue, while semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. Both compounds have been characterized in research involving appetite regulation, energy balance, metabolic signaling, and incretin-related pathways. Nova supplies Cagri + Semaglutide in a lyophilized vial that requires reconstitution with a suitable solvent before research use. Every batch is triple-tested by an independent, ISO/IEC 17025-accredited laboratory. For research use only. Not for human or animal consumption.